I tilgængelige data fra 1. linje- patienter behandlet med MabCampath, observeredes intet tab af CD52- ekspression omkring tidspunktet for sygdomsprogression eller død.
In data available from first line patients treated with MabCampath, loss of CD52 expression was not observed around the time of disease progression or death.